Excision BioTherapeutics Inc.

Amylyx Pharmaceuticals, Inc. announced Phase II/III results for AMX0035 in the treatment of amyotrophic lateral sclerosis (ALS) last year and hoped to obtain US Food and Drug Administration approval

Halfway through February, seven different sources of funding for health care and life science innovations have announced newly raised pools of cash totaling $2.2bn for a wide array of technologies, in

CRISPR gene editing has been a hot area of biotechnology for the past few years despite the absence of data in humans, but the field finally crossed a new threshold with initiation of the first indust

Below is Scrip’s monthly roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. Arraki